Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis

Kawagishi, Naoki; Suda, Goki; Nakamura, Akinobu; Kimura, Megumi; Maehara, Osamu; Suzuki, Kazuharu; Nakamura, Akihisa; Ohara, Masatsugu; Izumi, Takaaki; Umemura, Machiko; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Morikawa, Kenichi; Ogawa, Koji; Kudo, Yusuke; Nishida, Mutsumi; Miyoshi, Hideaki; Sakamoto, Naoya

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis

Kawagishi, Naoki; Suda, Goki; Nakamura, Akinobu et al.

PLOS ONE, 2018, 13(12), e0209615

Permalink : https://hdl.handle.net/2115/78822

このアイテムのアクセス数:620件（2026-08-11 15:37 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
journal.pone.0209615	pdf	1.45 MB	354

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/78822
タイトル	Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
著者	Kawagishi, Naoki ; Suda, Goki ; Nakamura, Akinobu ; Kimura, Megumi ; Maehara, Osamu ; Suzuki, Kazuharu ; Nakamura, Akihisa ; Ohara, Masatsugu ; Izumi, Takaaki ; Umemura, Machiko ; Nakai, Masato ; Sho, Takuya ; Natsuizaka, Mitsuteru ; Morikawa, Kenichi ; Ogawa, Koji ; Kudo, Yusuke ; Nishida, Mutsumi ; Miyoshi, Hideaki ; Sakamoto, Naoya
著者名 Kawagishi, Naoki
e-Rad_Researcher 20447460 著者名 Suda, Goki
e-Rad_Researcher 70552420 著者名 Nakamura, Akinobu
著者名 Kimura, Megumi
著者名 Maehara, Osamu
著者名 Suzuki, Kazuharu
著者名 Nakamura, Akihisa
著者名 Ohara, Masatsugu
著者名 Izumi, Takaaki
著者名 Umemura, Machiko
著者名 Nakai, Masato
著者名 Sho, Takuya
e-Rad_Researcher 80642446 著者名 Natsuizaka, Mitsuteru
著者名 Morikawa, Kenichi
e-Rad_Researcher 20735188 著者名 Ogawa, Koji
著者名 Kudo, Yusuke
e-Rad_Researcher 90404722 著者名 Nishida, Mutsumi
e-Rad_Researcher 30360902 著者名 Miyoshi, Hideaki
e-Rad_Researcher 10334418 著者名 Sakamoto, Naoya
言語	英語
発行日	2018
出版者	The Public Library of Science (PLOS)
収録物名	PLOS ONE
巻(号)	13(12)
ページ	e0209615
抄録	Aim: We comprehensively analyzed how hepatitis C virus (HCV) eradication by interferon (IFN)-free direct-acting-antiviral-agents (DAAs) affects liver steatosis and atherogenic risk. Methods: Patients treated with IFN-free-DAAs who underwent transient elastography before and at 24-weeks post-treatment, including controlled attenuation parameter (CAP), and achieved sustained viral response (SVR) were enrolled. The association between changes in liver steatosis, lipid-metabolism, and genetic and clinical factors was analyzed. Results: A total of 117 patients were included. The mean CAP and low-density lipoprotein cholesterol (LDL-C) levels were significantly elevated at SVR24. However, baseline LDL-C and CAP values were significantly negatively correlated with changes in these values after HCV eradication, indicating that in patients with high baseline values, the values generally decreased after HCV eradication. Mean small-dense LDL-C (sdLDL-C), which has greater atherogenic potential, was significantly elevated only in patients with both dyslipidemia (LDL-C >140 mg/dL) and liver steatosis (CAP >248 dB/m) at SVR24. Those patients had significant higher baseline BMI, LDL-C, and total-cholesterol levels. Conclusions: Generally, successful HCV eradication by IFN-free-DAAs decreases CAP and LDL-C in patients with high baseline values. However, elevated LDL-C was accompanied with elevated sdLDL-C only in patients with liver steatosis and dyslipidemia at SVR24; therefore, those patients may require closer monitoring.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution 4.0 International
EISSN	1932-6203
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1371/journal.pone.0209615